BioNTech SE (NASDAQ:BNTX) Shares Purchased by Candriam S.C.A.

Candriam S.C.A. lifted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 261.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 578,998 shares of the company’s stock after purchasing an additional 418,695 shares during the quarter. Candriam S.C.A. owned about 0.24% of BioNTech worth $46,526,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd boosted its stake in BioNTech by 2.5% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after buying an additional 116 shares in the last quarter. Covestor Ltd raised its stake in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. Arlington Capital Management Inc. boosted its position in shares of BioNTech by 10.0% in the first quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock worth $203,000 after buying an additional 200 shares during the period. Finally, Midwest Professional Planners LTD. raised its position in BioNTech by 7.2% during the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

Shares of BNTX stock opened at $89.94 on Friday. The stock’s fifty day simple moving average is $84.65 and its 200 day simple moving average is $89.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. BioNTech SE has a one year low of $76.53 and a one year high of $121.39. The firm has a market cap of $21.38 billion, a price-to-earnings ratio of 179.88 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same quarter last year, the firm earned ($0.86) earnings per share. BioNTech’s quarterly revenue was down 23.3% on a year-over-year basis. On average, analysts expect that BioNTech SE will post -2.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research note on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research report on Tuesday, August 27th. HSBC upgraded BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, TD Cowen lowered their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $109.09.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.